BioCorRx Q2 2026: Going Concern Warning, Revenue Halved, Cash Down to $21K
BICX is trading near its 52-week low of $0.152 (0.0% above the low) on elevated volume (3.7× avg).
Summary
BioCorRx's Q2 2026 10-Q shows a going concern warning, cash of only $21K, and revenue down 50.6% YoY. The company needs immediate capital to survive.
Key Events · Earnings and Guidance · BICX
-
Going Concern Warning
Cash of $21,237 and a working capital deficit of $8,231,326 raise substantial doubt about the company's ability to continue as a going concern for the next twelve months.
-
Revenue Decline
Q2 2026 revenue fell 50.6% YoY to $87,970, primarily due to lower Lucemyra distribution sales.
-
Material Weaknesses
Management disclosed material weaknesses in internal control over financial reporting, including insufficient GAAP experience and lack of segregation of duties.
-
Financial Restatement
The company revised Q1 2026 financials due to a revenue recognition error that overstated revenues by $135,471.
Analysis · BICX · Industrial Applications And Services
A critical liquidity crisis is laid bare in BioCorRx's Q2 2026 10-Q. Cash has dwindled to $21,237, and the company carries a working capital deficit of $8.2 million. Management explicitly states substantial doubt about its ability to continue as a going concern. Revenue fell 50.6% year-over-year to $87,970, driven by declining Lucemyra distribution sales. The filing also discloses material weaknesses in internal controls and revises Q1 2026 financials due to a revenue recognition error. Insiders provided $650,000 in new equity financing, but this is insufficient to fund operations for the next twelve months.
At the time of this filing, BICX was trading at $0.15 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.15 to $1.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.